Prior studies have demonstrated the neuroprotective effects of incretin-based medications across a range of neurological disorders, including PD, AD, epilepsy, stroke, and traumatic brain injury [52, 56, 68, 70–72, 101]. This evidence concerns the gene GCG and stroke disorder.